These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 11871143

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma.
    Nozoe T, Yasuda M, Honda M, Inutsuka S, Korenaga D.
    Hepatogastroenterology; 2007; 54(77):1422-5. PubMed ID: 17708268
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Clinico-pathological characteristics of colorectal cancer and serum anti-p53 antibodies.
    Bielicki D, Karbowniczek M, Sulzyc-Bielicka V, Kładny J, Boer C, Marlicz K, Domagała W.
    Pol J Pathol; 1999; 50(2):77-81. PubMed ID: 10481530
    [Abstract] [Full Text] [Related]

  • 25. Serum p53 antibodies in drainage blood from the azygos vein in patients with esophageal carcinoma.
    Kato H, Nakajima M, Fukuchi M, Miyazaki T, Manda R, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Tsukada K, Kuwano H.
    Anticancer Res; 2005; 25(5):3231-5. PubMed ID: 16101132
    [Abstract] [Full Text] [Related]

  • 26. Serum p53 antibodies: predictors of survival in small-cell lung cancer?
    Murray PV, Soussi T, O'Brien ME, Smith IE, Brossault S, Norton A, Ashley S, Tavassoli M.
    Br J Cancer; 2000 Dec; 83(11):1418-24. PubMed ID: 11076647
    [Abstract] [Full Text] [Related]

  • 27. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
    Wu CM, Tang R, Chen JR, Wu MC, Chien HT, Changchien CR, Hsieh LL.
    Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
    [Abstract] [Full Text] [Related]

  • 28. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
    Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh MW, Disis ML.
    J Clin Oncol; 2006 Feb 10; 24(5):762-8. PubMed ID: 16391298
    [Abstract] [Full Text] [Related]

  • 29. Detection of serum p53 antibodies in mucosal esophageal cancer and negative conversion after treatment.
    Shimada H, Arima M, Nakajima K, Koide Y, Okazumi S, Matsubara H, Miyazawa Y, Takeda A, Hayashi H, Yoshida T, Ochiai T, Isono K.
    Am J Gastroenterol; 1998 Aug 10; 93(8):1388-9. PubMed ID: 9707082
    [No Abstract] [Full Text] [Related]

  • 30. Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma.
    Gadducci A, Ferdeghini M, Buttitta F, Cosio S, Fanucchi A, Annicchiarico C, Genazzani AR.
    Anticancer Res; 1998 Aug 10; 18(5B):3763-5. PubMed ID: 9854491
    [Abstract] [Full Text] [Related]

  • 31. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
    Gumus E, Erdamar S, Demirel G, Horasanli K, Kendirci M, Miroglu C.
    Int J Urol; 2004 Dec 10; 11(12):1070-7. PubMed ID: 15663677
    [Abstract] [Full Text] [Related]

  • 32. Rapid and sensitive immunomagnetic-electrochemiluminescent detection of p53 antibodies in human serum.
    Yan G, Xing D, Tan S, Chen Q.
    J Immunol Methods; 2004 May 10; 288(1-2):47-54. PubMed ID: 15183084
    [Abstract] [Full Text] [Related]

  • 33. [Clinical significance of serum p53 antibody detection in a chemosensitivity assay in cases of human colorectal cancer].
    Takeda A, Shimada H, Nakajima K, Imaseki H, Okazumi S, Takayama W, Iwasaki K, Makino H, Natsume T, Kouno T, Kondo S, Suzuki T, Ochiai T, Isono K.
    Gan To Kagaku Ryoho; 2000 Jun 10; 27(6):879-83. PubMed ID: 10897215
    [Abstract] [Full Text] [Related]

  • 34. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
    Gao RJ, Bao HZ, Yang Q, Cong Q, Song JN, Wang L.
    Breast Cancer Res Treat; 2005 Sep 10; 93(2):111-5. PubMed ID: 16187230
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of the pattern and prognostic implications of anti-p53 in hepatocellular carcinoma.
    Akere A, Otegbayo JA.
    Singapore Med J; 2007 Jan 10; 48(1):41-4. PubMed ID: 17245515
    [Abstract] [Full Text] [Related]

  • 36. Detection of serum anti-p53 antibodies from patients with ovarian cancer in China: correlation to clinical parameters.
    Qiu T, Yang Q, Li XR, Yang H, Qiu LL, Wang L.
    Cancer Invest; 2007 Jan 10; 25(7):563-8. PubMed ID: 17952741
    [Abstract] [Full Text] [Related]

  • 37. p53 Antibodies in the sera of patients with various types of cancer: a review.
    Soussi T.
    Cancer Res; 2000 Apr 01; 60(7):1777-88. PubMed ID: 10766157
    [Abstract] [Full Text] [Related]

  • 38. [Correlation between serum p53 antibody and chemosensitivity in patient with esophageal cancer].
    Wang MH, Li YP, Wang XD, Zhang H, Xiong LH, Huang HZ.
    Ai Zheng; 2004 Apr 01; 23(4):467-70. PubMed ID: 15087041
    [Abstract] [Full Text] [Related]

  • 39. Anti-p53 antibodies and p53 protein expression in cholangiocarcinoma.
    Limpaiboon T, Sripa B, Wongkham S, Bhudhisawasdi V, Chau-in S, Teerajetgul Y.
    Hepatogastroenterology; 2004 Apr 01; 51(55):25-8. PubMed ID: 15011824
    [Abstract] [Full Text] [Related]

  • 40. [Serum anti-P53 antibodies (AB-anti-P53) in patients with advanced non-small cell lung cancer (NSCLC)].
    Skrzypski M, Szymanowska A, Janowicz A, Dziadziuszko R, Ramlau R, Kozielski J, Pilarska-Machowicz A, Dobrzańska Z, Bigda J, Krzakowski M, Jassem E, Jassem J.
    Pneumonol Alergol Pol; 2002 Apr 01; 70(7-8):353-8. PubMed ID: 12708076
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.